Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging its pioneering understanding of microRNA biology and chemistry to develop a pipeline of microRNA therapeutics designed to address a broad range_of_diseases with high unmet medical need, including autosomal dominant polycystic kidney disease (ADPKD) and other chronic kidney and rare diseases. Their approach aims to modulate fundamental disease pathways, offering potential for transformative treatments.
The headquarters serves as the central hub for research and development, clinical operations, corporate administration, and strategic leadership.
The facility includes modern laboratory spaces equipped for RNA therapeutic research and office environments designed for collaboration.
The work culture emphasizes innovation, scientific rigor, collaboration, and a patient-focused approach to drug development. Employees are often driven by the potential to make significant impacts in treating serious diseases.
Its location in a prominent biotech cluster allows for access to talent, research institutions, and potential collaborators, fostering innovation.
While Regulus Therapeutics is primarily based in the United States, its clinical development programs may involve trial sites and collaborations in multiple countries. The company engages with the global scientific and medical community to advance its research and therapeutic candidates.
10614 Science Center Drive, Suite 225
San Diego
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Regulus Therapeutics' leadership includes:
Regulus Therapeutics has been backed by several prominent investors over the years, including:
Regulus Therapeutics has seen key appointments in its executive team over the past year, strengthening its leadership in medical and business operations. No major C-suite departures have been publicly announced in the immediate last 12 months, following earlier transitions.
Discover the tools Regulus Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Regulus Therapeutics commonly uses the email format of the first initial followed by the last name.
[first_initial][last]@regulusrx.com
Format
jdoe@regulusrx.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Regulus Therapeutics announced its financial results for Q1 2024, highlighting progress in its RGLS8429 program for ADPKD, including enrollment completion for the third cohort of its Phase 1b MAD clinical trial and positive topline safety and PK/PD data....more
GlobeNewswire • April 2, 2024
The company reported favorable safety, tolerability, and pharmacokinetic data from the third cohort of its Phase 1b multiple-ascending dose (MAD) trial of RGLS8429. Changes in biomarkers, including polycystins, were observed, supporting the mechanism of action....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Regulus Therapeutics, are just a search away.